TherapeuticsMD Inc. stock drops 5.48 percent, ending two-day winning streak

6 articles · Updated · MarketWatch · Apr 27

Shares closed at $2.07 on Monday, underperforming competitors like AbbVie Inc., and trading volume reached 32,984, surpassing the 50-day average of 23,656.
The decline occurred during a mixed market session, with the NASDAQ Composite Index rising 0.20% and the Dow Jones Industrial Average falling 0.13%.
TherapeuticsMD Inc. now stands 29.83% below its 52-week high of $2.95, last reached on January 27th, reflecting ongoing volatility in the stock's performance.

Despite improving annual losses, why did TherapeuticsMD's quarterly net income suddenly drop over 300%?

With insiders buying heavily, is TherapeuticsMD's stock plunge a trap or a major buying signal?

In a booming women's health market, why is TherapeuticsMD evaluating a sale instead of capitalizing on growth?

AbbVie is investing billions while TXMD struggles. Does this signal an impossible market for smaller players?

Can a royalty-only model truly rescue a company with plummeting net income and a history of losses?